Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crunch Time for the Global Harmonization Task Force

This article was originally published in RAJ Devices

Executive Summary

Wind down, carry on much as before or be completely reinvented. These were three potential scenarios for the Global Harmonization Task Force that senior medical device regulators and industry executives from around the world were asked to consider at the plenary session of the 12th GHTF conference in Toronto on 12-14 May.

You may also be interested in...



EU: Rigel And Jazz Among Hopefuls At CHMP

Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.

EU: Stakes High For Novartis At Latest CHMP Meeting

Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.

Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings

Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP. 

UsernamePublicRestriction

Register

SC092876

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel